Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage. Durkacz noted that this area remains unmet by currently available treatments, highlighting the potential significance of Lucid-MS in the MS therapeutic landscape.
Durkacz also discussed Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. The product is part of a strategic spin-out, with Quantum retaining a 19.84% ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.) as of March 31, 2026, and a royalty agreement that includes 7% of sales until $250 million is reached, after which it drops to 3% in perpetuity. This structure provides Quantum with ongoing revenue potential from the consumer health market while focusing on its core pharmaceutical pipeline.
Looking ahead, Durkacz highlighted the company’s upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers. The transition to patient studies is a critical step in validating Lucid-MS’s efficacy and safety profile, and positive results could position Quantum as a key player in MS treatment. The company’s focus on myelin degradation, the underlying mechanism of MS, differentiates Lucid-MS from existing therapies that primarily address inflammation or symptom management. Preclinical models have shown Lucid-MS can prevent and reverse myelin degradation, a patented new chemical entity that could potentially modify disease progression.
The podcast appearance underscores Quantum’s efforts to increase visibility among investors and the medical community. With a portfolio that includes both a late-stage commercial product and a promising pipeline asset, the company is leveraging diversified revenue streams. The full press release is available at https://ibn.fm/8sLvp. For more information on Quantum BioPharma, visit their newsroom at https://ibn.fm/QNTM.
The implications of this announcement are significant for multiple sclerosis patients and investors alike. If Lucid-MS proves successful in Phase 2 trials, it could address a substantial unmet need in MS care—nerve damage and mobility loss. Additionally, unbuzzd(TM)’s market presence provides near-term revenue and validates the company’s ability to commercialize products. The combination of a potential breakthrough therapy and a revenue-generating consumer product offers a balanced risk profile for stakeholders. As Quantum progresses toward its Phase 2 trial, the biotech community will be watching closely for data that could reshape MS treatment paradigms.
